Inulin Supplementation's Impact on Gut Microbiota in Oral Lichen Planus Patients
Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa characterized by immune dysregulation, yet its pathogenesis remains incompletely understood, and no curative treatment has been established. Previous research indicates that patients with OLP exhibit gut dysbiosis, marked by reduced microbial diversity and a depletion of butyrate-producing bacteria. Given that butyrate plays a crucial role in promoting regulatory T-cell differentiation and supporting immune homeostasis, addressing this dysbiosis may provide a microbiota-directed strategy for immune modulation in OLP.
The current study aims to investigate the effects of inulin supplementation on gut microbiota and related immune markers in patients with OLP. This multicenter, double-blind, randomized, placebo-controlled parallel-group trial will enroll 80 patients diagnosed with OLP. Participants will be randomly assigned in a 1:1 ratio to receive either inulin (8 g/day) or a maltose placebo for four weeks, alongside standard care. The primary outcome will measure the change in the relative abundance of specified butyrate-producing gut bacteria from baseline to the end of the intervention at Week 6. Secondary outcomes will include changes in gut microbiota diversity, salivary microbiota composition, fecal short-chain fatty acid concentrations, peripheral blood regulatory T-cell counts, blood test parameters, and clinical symptoms of OLP.
The trial will follow the intention-to-treat principle, and appropriate statistical methods will assess between-group differences. This research is designed to evaluate whether a microbiota-directed intervention can modify gut microbial profiles and related immune markers in patients with OLP. The findings are expected to clarify the potential of inulin supplementation in altering gut microbiota and its implications for immunological health in OLP patients.
The trial is registered with the UMIN Clinical Trials Registry (UMIN-CTR), under the identifier UMIN000060840, as of April 1, 2026. The study will be conducted at Kyushu University Hospital and the Department of Oral and Maxillofacial Surgery at Okayama University Hospital, ensuring rigorous oversight and data management throughout the trial.
Participants will be informed about the study during routine outpatient care and will provide written consent before enrollment. The randomization process will ensure that participants are assigned to treatment groups in a manner that minimizes bias. The study aims to contribute valuable insights into the role of gut health in managing oral lichen planus, potentially paving the way for new therapeutic approaches that harness the power of dietary interventions.




